Targeting AXL in NSCLC
Aubhishek Zaman,1,2 Trever G Bivona1,2 1Department of Medicine, University of California, San Francisco, CA, USA; 2UCSF Helen Diller Comprehensive Cancer Center, University of California, San Francisco, CA, USACorrespondence: Trever G Bivona Email trever.bivona@ucsf.eduAbstract: State-of-the-art can...
Enregistré dans:
Auteurs principaux: | Zaman A, Bivona TG |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/01e16318a1f14041832b1e2fd09330bd |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
AXL receptor tyrosine kinase as a therapeutic target in NSCLC
par: Okimoto RA, et autres
Publié: (2015) -
Targeting MERTK and AXL in <i>EGFR</i> Mutant Non-Small Cell Lung Cancer
par: Dan Yan, et autres
Publié: (2021) -
Polo-like kinase 1 inhibition in NSCLC: mechanism of action and emerging predictive biomarkers
par: Stratmann JA, et autres
Publié: (2019) -
AXL receptor is required for Zika virus strain MR-766 infection in human glioblastoma cell lines
par: Samuel D. Zwernik, et autres
Publié: (2021) -
Immunotherapy for Stage III NSCLC: Durvalumab and Beyond
par: Fitzpatrick O, et autres
Publié: (2021)